Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in Mild Alzheimer's Disease
NCT03056495Phase 1Terminated
- Sponsor
- German Center for Neurodegenerative Diseases
- Start
- Sep 2017
- Primary completion
- Mar 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vorinostat in Alzheimer's disease (AD), sponsored by German Center for Neurodegenerative Diseases. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Sep 2017; status: terminated.
02
Drugs
vorinostat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03056495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056495.